Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Certican in Kidney Transplant Patients
NCT01594268Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in kidney transplant rejection, sponsored by Novartis. Primary endpoint: Number of participants with serious adverse events at 12 weeks. Started Mar 2012; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01594268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594268.